Urigen Pharmaceuticals Completes $257,000 Financing

BURLINGAME, CA, Jan 12 (MARKET WIRE) --
Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical
company focused on the development of treatments for urological disorders
and pain, has secured financing totaling $257,000 from Platinum - Montaur
Life Sciences, LLC. This increases Platinum's total investment in Urigen
to $2.357 million. The proceeds from the financing will be used to
provide the financial flexibility to advance partnering and M&A
discussions for Urigen's URG101 program for Painful Bladder Syndrome and
URG301 program for Overactive Bladder.

"Securing this financing provides the resources we need to continue
ongoing strategic discussions," said William J. Garner, Chief Executive
Officer of Urigen Pharmaceuticals. As part of this process, the Company
has engaged a strategic advisor who will work with management to identify
and develop additional opportunities to strengthen Urigen's competitive
position and to advance its urological programs by identifying and
assessing potential strategic partners and additional financing
alternatives.

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic products
for urological disorders. Urigen's two lead programs target significant
unmet medical needs and major market opportunities in urology. Urigen's
URG101, a proprietary combination of approved drugs that is instilled into
the bladder, targets painful bladder syndrome, which affects approximately
10.5 million men and women in North America. Urigen's URG301, a
proprietary dosage form of an approved drug that is locally delivered to
control urinary urgency, targets acute urgency in females diagnosed with
an overactive bladder, another major unmet need that is insufficiently
managed by presently available overactive bladder drugs. For further
information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking terminology
such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "potential," "predict,"
"should," or "will," or the negative thereof or other variations thereon
or comparable terminology. Urigen has based these forward-looking
statements on current expectations, assumptions, estimates and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking statements
are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond its control. Given these risks
and uncertainties, investors and security holders are cautioned not to
place undue reliance on such forward-looking statements. Urigen does not
undertake any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments.

Contact:

Urigen Pharmaceuticals, Inc.
William J. Garner, MD
Chief Executive Officer
415-781-0350
www.urigen.com

Copyright 2009, Market Wire, All rights reserved.

-0-